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Abstract
Caveolin-1 (Cav-1) is a regulatory protein of the arterial wall, but its role in human atherosclerosis remains unknown. We
have studied the relationships between Cav-1 abundance, atherosclerotic plaque characteristics and clinical manisfestations
of atherosclerotic disease.We determined Cav-1 expression by western blotting in atherosclerotic plaques harvested from
378 subjects that underwent carotid endarterectomy. Cav-1 levels were significantly lower in carotid plaques than non-
atherosclerotic vascular specimens. Low Cav-1 expression was associated with features of plaque instability such as large
lipid core, thrombus formation, macrophage infiltration, high IL-6, IL-8 levels and elevated MMP-9 activity. Clinically, a down-
regulation of Cav-1 was observed in plaques obtained from men, patients with a history of myocardial infarction and
restenotic lesions. Cav-1 levels above the median were associated with absence of new vascular events within 30 days after
surgery [0% vs. 4%] and a trend towards lower incidence of new cardiovascular events during longer follow-up. Consistent
with these clinical data, Cav-1 null mice revealed elevated intimal hyperplasia response following arterial injury that was
significantly attenuated after MMP inhibition. Recombinant peptides mimicking Cav-1 scaffolding domain (Cavtratin)
reduced gelatinase activity in cultured porcine arteries and impaired MMP-9 activity and COX-2 in LPS-challenged
macrophages. Administration of Cavtratin strongly impaired flow-induced expansive remodeling in mice.This is the first
study that identifies Cav-1 as a novel potential stabilizing factor in human atherosclerosis. Our findings support the
hypothesis that local down-regulation of Cav-1 in atherosclerotic lesions contributes to plaque formation and/or instability
accelerating the occurrence of adverse clinical outcomes. Therefore, given the large number of patients studied, we believe
that Cav-1 may be considered as a novel target in the prevention of human atherosclerotic disease and the loss of Cav-1
may be a novel biomarker of vulnerable plaque with prognostic value.
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Introduction
Atherosclerotic plaque formation, destabilization and rupture
with subsequent thrombus formation give rise to acute coronary
syndromes [1], symptomatic carotid artery disease [2] and sudden
cardiac death [3]. Plaque rupture is associated to an elevated
inflammatory response [4], increased proteolytic activity [5;6] and
intra-plaque bleeding [7]. The current lack of knowledge about
the natural history of human atherosclerotic disease and plaque
progression restricts the possibility to identify subjects at risk for
cardiovascular events. In order to evaluate the relationship
between local protein expression in atherosclerotic plaques and
future vascular events, the ATHERO-EXPRESS vascular bio-
bank was established [8] . The main goal of this study is to identify
the expression patterns of specific proteins expressed within the
vascular tree that may make patients prone to suffer cardiovas-
cular events in all vascular territories. These proteins, diffusely
expressed in the vasculature, could then be locally detected using
local molecular imaging or in endarterectomy specimens, and
serve as a surrogate marker to identify the patient at risk for future
adverse cardiovascular events, the so-called vulnerable patient [9].
In this context, we have tested the possibility that Caveolin-1 (Cav-
1) plaque abundance is related to plaque and patient stability.
Cav-1 is the main coat protein of caveolae and is expressed by
different vascular cells [10]. Caveolae and Cav-1 have emerged as
novel targets in the control of various important cellular processes
involved in the maintenance of cardiovascular homeostasis such as
protein trafficking, lipid metabolism and signal transduction [11].
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atherosclerosis still remains controversial and not well understood
[12]. Cav-1/ApoE double-knockout mice show less lipid accumu-
lation in the aorta, while the absence of Cav-1 promotes smooth
muscle cells proliferation increasing intimal hyperplasia upon
carotid injury [13;14]. In addition, the analysis of plaques from
hypercholesterolemic rabbits and humans showed reduced Cav-1
levels, suggesting athero-protective actions for Cav-1 [15;16].
However; the study of the relationships between Cav-1 abun-
dance, atherosclerotic plaque phenotype and clinical manifesta-
tions of atherosclerotic disease has not been undertaken yet.
Therefore, we determined Cav-1 expression in carotid
atherosclerotic plaques from a cohort of 378 patients undergoing
carotid endarterectomy obtained from the ATHERO-EXPRESS
study. We hypothesized that plaque levels of Cav-1 might be
related to plaque morphology, inflammation and matrix metallo-
protease (MMP) activity. We also investigated if local Cav-1
expression levels in the carotid plaque were related to clinical
characteristics. In addition, the design of the bio-bank study
allowed the execution of a follow up with the objective to study
the predictive value of local Cav-1 expression for the future
development of cardiovascular adverse events and thus might help
identifying patients at risk. Additionally, we hypothesized that
potential associations of Cav-1 expression with adverse outcomes
could be explained by an inhibitory effect on MMP activity in the
atherosclerotic lesion. In order to address this hypothesis we
further analyzed the effect of Cav-1 on intimal hyperplasia in Cav-
1 null mice and whether an increased intimal hyperplasia response
could be attenuated by MMP blockade. In addition, we studied
the impact of Cav-1 scaffolding domain (CSD) on gelatinase
activity, COX-2 expression and expansive arterial remodeling in
vitro and in mice.
This clinical and pre- clinical data provides evidence supporting
an important role for Cav-1, and its related peptides, in vascular
pathologies such as intimal hyperplasia, expansive remodeling and
human atherosclerotic plaque destabilization and rupture.
Methods
Human study
The Athero-Express vascular bio-bank. Athero-Express is
an ongoing vascular bio-bank project with the goal to investigate
locally expressed plaque markers in relation to clinical
presentation and clinical outcome [8]. The bio-bank project is
running in two Dutch hospitals and was approved by the ethical
commitees of the Antonius hospital Nieuwegein, The Netherlands
and the UMCU, Utrecht, the Netherlands. Written informed
consent is obtained from all patients. Criteria for patient selection
for carotid endarterectomy (CEA) were based upon the
recommendation of NASCET and ESCT for symptomatic
patients and ASCT for asymptomatic patients [17;18]. Stenosis
degree was assessed by duplex. At baseline, medication use,
cardiovascular risk factors, history of cardiovascular disease, and
other baseline characteristics were retrieved from questionnaires.
Additional clinical data were recorded from patient charts. Lipid
spectra and hs-CRP were measured in blood samples drawn at
baseline. For the current study, carotid endarterectomy patients
between the start of the study in April 2002 until April 2006 were
included.
Follow-up Protocol and Clinical Outcome Events. After
carotid surgery, patients were followed yearly up to 3 years (mean:
23 months). The primary outcome was defined as vascular event:
the composite of vascular death, non-fatal myocardial infarction,
non-fatal stroke, non-fatal rupture of an abdominal aortic
aneurysm, and vascular surgical intervention, whichever
occurred first. Additional outcomes were: 1) myocardial
infarction (fatal and non-fatal) and coronary revascularization
and 2) ischemic stroke. Definitions and assessment procedures of
the outcome events were described previously [19].
Tissue Sampling. Carotid endarterectomy was performed
by an open, non-eversion technique with careful dissection of the
atherosclerotic plaque. Following excision, the plaque was
immediately transferred to the laboratory to undergo
standardized processing. First, it was divided into 5mm cross-
sectional segments. The culprit lesion, defined as the segment with
greatest plaque burden, was fixated in 4% formalin for 7 days and
then decalcified in EDTA and embedded in paraffin. The other
segments were snap frozen in liquid nitrogen and stored at 280uC.
Protein extraction was performed on the carotid segments
adjacent to the culprit lesion by mechanical crushing followed
by 1) protein isolation with TriPure reagent, according to the
manufacturer’s protocol (Boehringer Mannheim, Germany) and 2)
by dissolving in 40 mM Tris-HCl (pH=7.5) at 4uC. Segments of
macroscopically non-atherosclerotic mammary arteries (n=9)
obtained during coronary artery bypass surgery served as a non-
diseased control.
Histological Assessment of Carotid Atherosclerotic
Plaques. All plaques were characterized as described earlier
[8]. The following stainings were applied on serial cross-sections
(5 mm) of paraffin embedded tissue and semi-quantitatively
analyzed as no, minor, moderate or heavy staining by observers
blinded for patient characteristics: macrophages (CD68), smooth
muscle cells (alpha-actin), collagen (picro-sirius red), calcifications
(HE) and thrombus (HE and picro-sirius red). The size of the lipid
core was visually estimated as a percentage of plaque area using
H&E and picro-sirius stainings (,10%, 10%–40%, .40%). In
addition, computerized measurements of CD68 and alpha-actin
were performed to assess macrophage and smooth muscle content
respectively. Representative images of semi-quantitative staining
can be found in [20].
Determination of Intra-plaque Interleukin levels, MMP
activity and EMMPRIN levels. Interleukin-6 and -8 (IL-6 and
IL-8) concentrations were determined with a multiplex suspension
array system according to the manufacturer’s protocol (Bio-Rad
Laboratories, Hercules, CA). MMP-2 and MMP-9 activities and
Extracellular Matrix Metalloproteinase Inducer (EMMPRIN)
levels were measured in a randomly selected subgroup of 128
patients. MMP-2 and MMP-9 activity measurements were
performed with Biotrak activity assays RPN 2631 and RPN
2634, respectively (Amersham Biosciences, Buckinghamshire,
UK). EMMPRIN expression levels were determined by Western
blotting as described previously [21]. The ratio between the two
forms of EMMPRIN (58 KD highly glycosylated and a 45 KD less
glycosylated forms) was calculated.
Cav-1 Immunohistochemistry. Serial cross-sections (5 mm)
from carotid endarterectomy specimens and mammary arteries
were deparaffinized and rehydrated, boiled in sodium citrate and
blocked in 10% normal goat serum. The sections were incubated
for 1 hour at room temperature with 0.2 mg/ml polyclonal rabbit-
anti human-Cav-1 antibody (610059, BD biosciences, Franklin
Lakes, NJ), as determined by titration, followed by biotinylated
goat-anti-rabbit antibody (Vector, Burlingame, CA) and
horseradish peroxidase (HRP) labeled streptavidin (Vector).
Staining was developed with AEC substrate with Mayer’s
haemotoxylin as counterstaining. Negative controls were
obtained avoiding the primary antibody. Double labeling for
Cav-1 and alpha-actin SMC (Sigma,St Louis) and CD34 (Dako,
Denmark) were also performed.
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Animals were housed conformed to the Guide for the care and
use of Laboratory Animals (NIH publication No.85-23, 1985) and
all experiments were approved by the ethical committee on animal
experiments of the University Medical Center, Utrecht. BALB/c
mice, Cav-1 null mice (Cav-1
tm1Mls) and appropriate Wild type
(WT) genetic background controls were purchased by the Jackson
laboratories (Bar Harbor, MA).
Induction of Intimal Hyperplasia and Matrix-
Metalloprotease (MMP) inhibition. A group of Cav-1 null
mice were treated daily with doxycycline (DOX), an orally
available MMP inhibitor, in drinking water at the dose of 30 mg/
kg/day as used earlier [22] .The treatment started a week before
cuff placement and was continued for another 3 weeks.
Polyethylene cuffs, to induce intimal hyperplasia, were placed
around the right femoral artery in WT (n=11), Cav-1 null (n=12)
and Cav-1 null+DOX (n=11) mice. The animals were sacrificed 3
weeks after cuff placement and the femoral arteries were harvested
and analyzed as reported before [23] .
Recombinant Peptides Experiments. Synthetic peptides
corresponding to scaffolding domain of human Caveolin-1
(residues 82–101) (Cavtratin) and scrambled version were
prepared as previously reported [24;25] . For in vitro
experiments, final concentration of each peptide was achieved
by diluting the stock in culture medium. For in vivo experiments,
peptides were dissolved in 30% dimethyl sulfoxide (DMSO)
solution in 0.9% saline buffer (Braun) and mini-osmotic pumps
(Alzet) with an internal volume of 200 ml and infusion rate of
0.5 mL/ hour were filled with a daily dose of 1.5 mg/kg of
Cavtratin or scrambled peptides. Subsequently, mini-osmotic
pumps were attached to a small flexible catheter (Alzet).
Catheters were surgically connected to the jugular vein of
BALB/c mice and pumps were placed subcutaneously.
Thereafter, a right carotid ligation was performed as a model
for expansive remodeling in BALB/c (n=14), BALB/c+scrambled
(n=6) and BALB/c+Cavtratin (n=6) as described earlier [26].
Non-ligated arteries (BALB/c, n=10) were used as a reference (0
days). After 4 weeks, the contralateral left carotids were pressure-
fixed, harvested and embedded in paraffin. Total circumference
area (EEL area), intimal and luminal area were measured after
elastin staining and compared to non-ligated carotids (0 days).
Expansive remodeling was defined as an increase in EEL area
compared with the reference group. Data were analyzed by
ANOVA.
Gelatin and in situ Zymography. Gelatin zymography was
performed as described previously [27]. For in situ zymography,
porcine arterial rings were embedded in Tissue-Tek (Sakura),
sectioned (5 mm) and incubated at 37uC overnight with a
fluorogenic gelatin substrate (DQ gelatin, Molecular Probes) to a
final concentration of 25 mg/mL. Proteolytic activity was detected
under the microscope as green fluorescence at 530 nm.
Culture of Porcine Arterial Rings. Internal mammary
arteries were surgically harvested from 2 adult male pigs and sliced
in approximately 0.5 cm rings. After washing with PBS, arterial
rings were immediately frozen (0 days) and the remaining
fragments were incubated overnight in presence or absence of
Cavtratin or scrambled peptides in a serum-free D-MEM (Gibco)
and after extensive washing were cultured in 5% FBS D-MEM for
3 days. Thereafter, samples were processed for gelatin and in situ
zymography.
Human Cav-1, murine EMMPRIN and COX-2 Western
Blotting. Equal amounts of total protein were denaturized and
subjected to a SDS-PAGE in 10% or 12% polyacrylamide gels.
Proteins were transferred onto nitrocellulose membranes (Schleier
& Schuell, Dasel, Germany) and correct transfer was checked by
Ponceau Red S staining. The membranes were incubated with
either polyclonal rabbit-anti-human Cav-1 antibody (0.1 mg/mL,
BD biosciences, Franklin Lakes, NJ), polyclonal goat anti
EMMPRIN (0.4 mg/mL , G-19 Santa Cruz, Biotechnology) or
polyclonal rabbit anti murine COX-2 (0.5 mg/mL, Cayman
Chemicals, Ann Arbor, Mi) followed by incubation with
appropriate HRP conjugated secondary antibodies. Signal
detection was performed by enhanced chemiluminescence
(Sigma, Saint Louis, MO). For western blotting in CEA samples,
a pooled sample of mammary arteries (n=6) was loaded on each
gel as a positive control. Accordingly, in every gel, expression
levels of Cav-1 in pooled mammary arteries were considered as
100. Cav-1 expression levels in non-atherosclerotic mammary
arteries (n=3) and CEA samples were standardized and calculated
as percentages relative to standard positive control.
Cell Culture. Raw-264.7 murine macrophages were
obtained from ATCC (Manassas, VA) and grown and
propagated accordingly to manufacture’s recommendations.
Data Analysis. Comparison of Cav-1 expression levels
between different artery types and different patient groups was
done by Mann Whitney U tests. The Mann Whitney U test was
also used to test the association between Cav-1 measurements and
semi-quantitatively measured plaque characteristics, comparing no
and minor staining to moderate and heavy staining. For survival
analysis, Cav-1 levels were dichotomized at the median. The
group with low Cav-1 expression levels (,median) was compared
with the group high Cav-1 measurements (.=median) by
Kaplan-Meier survival analysis. Cox Proportional Hazard
analysis was used to compute Hazard ratios (HR) with 95%
confidence intervals [CI] and to adjust for sex, gender and plaque
overall phenotype. Data from animal, ex vivo and cultured cells
were analyzed by Mann-Whitney U and ANOVA tests. P-values
,0.05 were considered statistically significant.
Results
Baseline characteristics of the patient population are depicted in
Table 1. In total 378 patients were included in this report, with a
mean age of 67.4+/28.8 years.
Cav-1 expression pattern in Human Atherosclerotic
Lesions
Cav-1 antibody was able to detect two bands with a relative
molecular weight of 24KD and 22 KD demonstrating the
presence of the two known isoforms of Cav-1 (a and b);
(Figure 1A) Cav-1 protein expression levels were strongly reduced
in atherosclerotic plaques compared with non-atherosclerotic
mammary arteries (Figure 1B). The carotid plaques showed 64%
lower expression levels compared to mammary arteries (95% CI:
[31%–96%]) (Figure 1B).
By immunohistochemistry, we found that both mammary
arteries and human atherosclerotic lesions expressed Cav-1
(Figure 2). In mammary arteries, Cav-1 staining was distributed
throughout the intimal, medial and adventitial layers. In carotid
plaques, Cav-1 was frequently found in smooth muscle cells, the
endothelium of neovascularized areas and endothelium aligning
the vessel lumen. Co-localization with macrophages was not
observed. No staining was observed in non-immune controls
(Figure 2).
Cav-1 Abundance and Plaque Characteristics
We further examined the relationships between Cav-1 expres-
sion levels and different plaque characteristics. Plaques with an
Caveolin-1 and Atherosclerosis
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compared with fibrous plaques (p,0.001; Table 2). In addition,
Cav-1 levels were significantly lowered in plaques with unstable
characteristics such as high macrophage staining (p=0.04), low
smooth muscle cell staining (p,0.001), low collagen staining
(p=0.02), and high amount of thrombus (p=0.005). There was no
association between Cav-1 expression levels and extent of
calcifications.
Cav-1 Abundance, Proteolytic Activity and Inflammation-
Human data
Next, we investigated the relationships between Cav-1 expres-
sion levels, local MMP activity, expression of the MMP-inducer
CD147/EMMPRIN and the levels of pro-inflammatory cytokines
(Figure 3). High MMP-9 activity was observed in patients with low
Cav-1 expression levels (p,0.001) while there was no significant
correlation between Cav-1 levels and MMP-2 (Figure 3A, B).
Previously, we observed positive associations between MMP-9
expression and 58kD glycosylated EMMPRIN and MMP-2 and
45KD EMMPRIN levels, respectively [21]. Therefore, we studied
the association between EMMPRIN glycosylation and Cav-1
expression. A significant association between Cav-1 expression
and EMMPRIN glycosylation levels was observed (Figure 3E,
p=0.04). Low Cav-1 levels were associated with high IL-6 levels
(p=0.006) and IL-8 levels (p,0.001). These associations were not
a mere reflection of constitutional expression of Cav-1 on certain
cell types. As an example, Figure 3 (panel F-I) shows that the
inverse associations between Cav-1 and MMP-9 are preserved
within subgroups based on the number of smooth muscle cells and
macrophages. Similar results were obtained for MMP-2, IL-6, IL-
8, and EMMPRIN glycosylation (data not shown).
Cav-1 Abundance, Clinical Presentation and Follow up
Having established the inverse association between local low
levels of Cav-1 and the characteristics of a local vulnerable plaque
phenotype, we investigated if local Cav-1 expression levels were
related to clinical presentation at baseline and the occurrence of
adverse events due to progression of atherosclerotic disease during
follow up. Symptomatic patients presenting with transient
ischemic attack or stroke had lower Cav-1 levels than asymptom-
atic patients but this difference did not reach statistical significance
(Table 3; p=0.13). There was no association between hyperten-
sion, diabetes, smoking and Cav-1 (Table 3). Women showed
clearly higher levels compared with men (36.1 vs. 15.8; p,0.001).
Patients with a history of myocardial infarction had lower levels of
Cav-1 than patients with no such history (13.3 vs. 20.5; p=0.04).
Low levels of Cav-1 were found in patients with restenotic lesions:
6.1 vs. 19.7 (p=0.04) (Table 3).
Total follow-up included 625 patient years (mean 23 months)
and 13 patients were lost to follow-up (3%). In total, 92 outcome
events occurred (Table 4). Patients with vascular events within 30
days of surgery (8/378) had significantly lower Cav-1 levels than
patients with no peri-operative events (Figure 4A; p=0.03) and all
of these patients had Cav-1 levels lower than the median Cav-1
level (p=0.005). As shown in Figure 4B, this difference tended to
persist during the first year after the intervention. However, no
significant difference persisted during longer follow-up. At longer
follow up,the Hazard Ratio (HR) for vascular events (Cav-1
.=median vs. Cav-1 ,median) was 0.77 [0.48–1.23] (Figure 4B).
The HR for cardiac events and ischemic strokes separately were
similar: 0.76 [0.36–1.59] and 0.67 [0.22–2.03] respectively.
Adjusting for age, sex and overall plaque phenotype did not
Table 1. Baseline characteristics of the studied population.
n( % )
patient number 378
age, years (sd) 67.4 (8.8)
male 258 (68%)
hypertension 247 (70%)
diabetes 70 (20%)
smoking 88 (26%)
body mass index, kg/m
2 (sd) 26.7 (4.5)
total cholesterol, mmol/l 5.0 (1.1)
HDL cholesterol, mmol/l 1.2 (0.37)
LDL cholesterol, mmol/l 3.0 (1.0)
triglycerides, mmol/l 2.1 (1.1)
hs-CRP, mg/l (IQR) 3.4 (1.6–6.9)
prior ipsilateral CEA 12 (3%)
prior vascular intervention 139 (35%)
history of myocardial infarction 72 (20%)
carotid stenosis grade
50–64% 12 (3%)
65–89% 133 (35%)
90–99% 232 (62%)
symptoms
asymptomatic 87 (23%)
ocular symptoms 51 (14%)
TIA 130 (35%)
stroke 102 (28%)
doi:10.1371/journal.pone.0002612.t001
Figure 1. Cav-1 expression pattern in normal and atheroscle-
rotic lesions. A: representative Western Blot. ‘‘C’’ denotes control
(pooled sample), ‘‘M’’ denotes mammary arteries, ‘‘CEA’’ denotes carotid
plaques. Detection of Cav-1 a and b isoforms (22 and 24 KD; above) and
b-actin (42 KD; below) are shown. B: Quantification of Cav-1protein
levels in carotid artery vs. control mammary arteries (mean and SE). *
p=0.001. Note that b2actin and Cav-1 expression patterns differ
completely, indicating the specificity of Cav-1 down-regulation in CEA
samples.
doi:10.1371/journal.pone.0002612.g001
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[0.51–1.36], HR for cardiac events 0.68 [0.31–1.48] and HR for
ischemic stroke 0.85 [0.25–2.89].
Cav-1 Abundance, Proteolytic Activity and Inflammation,
in vitro and Animal Data
We further extended the study on the associations between Cav-
1 and MMP expressions by analyzing the contribution of
gelatinase activity to intimal hyperplasia in Cav-1 null mice upon
femoral artery injury using peri-adventitial cuffs.
Morphometric analysis revealed a significant increase in intimal
area in Cav-1 null mice (WT=132561069 mm
2 vs Cav-1
null=362761121 mm
2 p=0.003, Figure 5A). Medial area did
not differ (WT=914862340 mm
2 vs Cav-1 null=94496
2815 mm
2 p=0.4, Figure 5B) whereas intima-media ratio
(WT=0.1260.1 vs Cav-1 null=0.3860.09 p=0.001) was
significantly larger in the Cav-1 null mice (Figure 5C).
Treatment with the MMP inhibitor doxycycline (DOX),
significantly corrected the increased intimal hyperplasia response
in Cav-1 null mice (Cav-1 null+DOX=19756620, Cav-1 null-
DOX=362761121 mm
2 p,0.001, Figure 5A) while media area
was not affected (Cav-1 null+DOX=921761189 Cav-1 null-
DOX=944962815 mm
2 p=0.5, Figure 5B). Intima-media ratio
also significantly reduced compared to untreated Cav-1 null mice
(Cav-1 null+DOX=0.2160.06 Cav-1-DOX=0.3860.09
p,0.001, Figure 5C).
To study if Cav-1 via its scaffolding domain (CSD) is involved
in MMP regulation and the expression of pro-inflammatory
mediators, we next evaluated the effect of cell-permeable
synthetic peptides derived from the human CSD known as
Cavtratin on gelatinolytic activity and cycloxygenase-2 (COX-2)
expression in cultured murine Raw-264.7 macrophages. Peptides
were efficiently taken up by the cells after 6 hours incubation
(data not shown). Raw-264.7 cells were treated with 10 mMo f
Cavtratin or scrambled peptides for 24 hours and culture media
was subjected to gelatin zymography. Cavtratin treatment
significantly reduced MMP-9 levels (p=0.02) after 24 hours of
incubation (Figure 6A and B). The incubation of Raw-264.7 with
the scrambled peptides did not affect MMP-9 levels in the
culture supernatant or control b2Actin expression levels in the
total lysate (Figure 6A and B). Very little, almost undetectable
signal from MMP-2 was detected (data not shown). Since human
carotid plaques showed an inverse relationship between Cav-1
expression levels and EMMPRIN glycosylation status, we
additionally investigated whether the effect of Cavtratin on
Figure 2. Cav-1 immunohistochemistry. A, C: Cav-1 staining on
carotid plaques (red, 200x magnification). B: Endothelial staining (CD34,
brown) on a consecutive section of A showing co-localization of Cav-1
and endothelium. D: Alpha-actin smooth muscle cell staining (brown)
on a consecutive section of C, showing co-localization of Cav-1 and
smooth muscle cells. E: Double-staining of Cav-1(red) and CD34 (blue),(
200X magnification). F: Double staining of Cav-1 (blue) and Alpha-actin
smooth muscle cell sataining (red) ( 200X magnification). G: Cav-1
staining on a mammary artery, showing staining throughout the intima,
media and adventitia. (100x magnification). H: Negative control of Cav-1
staining in a consecutive section of G, avoiding the primary antibody.
Sections were counterstained with haemotoxylin except the double-
stained sections (E and F) .
doi:10.1371/journal.pone.0002612.g002
Table 2. Relationships between plaque histology and Cav-1 protein expression levels.
Cav-1 levels p-value
fibrous fibro-atheromatous atheromatous
overall phenotype 26.2 (11.7–53.3) 25.0 (7.7–56.0) 13.3 (4.5–32.9) ,0.001
no staining minor staining moderate staining heavy staining
macrophage staining 24.0 (5.7–54.4) 23.0 (10.3–51.2) 20.0 (5.7–47.4) 14.5 (3.6–30.7) 0.04
smooth muscle cell
staining
5.7 (2.3–27.4) 11.9 (3.5–25.4) 19.6 (6.4–45.7) 34.4 (18.2–71.2) ,0.001
collagen staining 15.6 (3.7–33.8) 20.4 (6.7–47.9) 26.1 (12.0–49.9) 0.02
calcifications 23.5 (5.9–50.1) 18.4 (4.9–35.7) 15.9 (7.4–41.2) 26.2 (7.7–55.7) 0.57
thrombus 30.1 (13.0–53.3) 17.4 (5.7–46.0) 14.6 (3.5–33.1) 10.7 (2.5–27) 0.005
The values given are the median Cav-1 levels and interquartile range in the respective staining group. P-values were calculated comparing Cav-1 expression levels
between no and minor staining vs. moderate and heavy staining, and in case of overall phenotype: fibrous vs. atheromatous.
doi:10.1371/journal.pone.0002612.t002
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levels of EMMPRIN. As shown in Figure 6A and C, the ratios
between low and higly-glycosylated EMMPRIN levels were not
affected by any treatment (p=0.7).
To test if Cavtratin might prevent the MMP-9 activation and
the induction of COX-2, Raw-264.7 cells were challenged with
E.coli Lipopolysaccharide (LPS) in order to induce gelatinase
activation and COX-2 expression. As expected, addition of LPS
(10 ng/ml) for 20 hours, up-regulated total MMP-9 levels in the
culture medium and COX-2 expression in the cell lysates
(Figure 7). This up-regulation of active MMP-9 was significantly
blocked by pre-incubation of cells with 10 mM Cavtratin (p=0.01)
(Figure 7 A and B). Induction of COX-2 expression after LPS
stimulation was also markedly reduced by pre-incubation with
Cavtratin (p,0.001). In contrast, pre-incubation of Raw-264.7
with scrambled peptides did not show any inhibitory effect either
on MMP-9 or COX-2 levels (p=0.4) (Figure 7 A, B and C). In all
cases, no differences were found in b-Actin expression (Figure 7 A).
We also determined EMMPRIN levels after LPS stimulation. As
shown in Figure 7 A and C addition of LPS to Raw-264.7 did not
have any impact on EMMPRIN expression levels. Pre-incubation
of cells with either Cavtratin or scrambled peptides did not affect
EMMPRIN levels (Figure 7 A and C).
In parallel, this inhibitory effect of Cavtratin on gelatinolytic
activity was also evaluated in arterial rings from porcine mammary
artery that were cultured for 3 days with and without Cavtratin or
scrambled peptide (10 mM). Gelatin zymography showed a
significant down-regulation of the total lytic activity corresponding
to MMP-2 (p=0.02) and MMP-9 levels (p=0.01) between
Cavtratin and scrambled peptide treated or non-treated arteries
(Figure 8 A, B and C). In situ zymography of the arteries suggests a
reduction in total gelatinase activity in the presence of 10 mMo f
Cavtratin (Figure 8D) while treatment with scrambled peptides did
not show any effect (Figure 8 D).
Effect of Cav-1 Scaffolding Domain on Arterial Expansive
Remodeling
Since compelling evidence is pointing to arterial expansive
remodeling as a major determinant of plaque vulnerability
[28;29], we next questioned whether this process might be
targeted by Cavtratin. For this, we evaluated the impact of
Cavtratin administration on BALB/c mice by using the carotid
artery contra-lateral to the ligation as a model in which only
expansive remodeling takes place. Four weeks after ligation, the
contra-lateral arteries showed an increase in total EEL area
(2333065644 mm
2, p=0.001 compared to non-ligated control
arteries) (Figure 9). Mice treated with scrambled peptides (1.5mg/
Kg/day) did not show any difference in EEL area increase
compared to untreated arteries (1994465434 mm
2) (Figure 9).
However, treatment of BALB/c mice with Cavtratin (1.5mg/Kg/
day) resulted in a significant reduction in EEL area
(73564838 mm
2, p=0.02 compared to non-ligated control
arteries) (Figure 9).
Discussion
The present study identifies Cav-1 as a potential stabilizing
factor in human atherosclerosis. Cav-1 levels were lower in
Figure 3. Relationships between Cav-1, Interleukin levels, MMP
activity and EMMPRIN levels A, B, C, D: MMP-2, -9 and IL-6,-8 vs.
Cav-1 protein expression levels. E: EMMPRIN 45/58KD ratio vs. Cav-1
protein expression levels. F, G: Analysis of association between MMP-9
and Cav-1 levels in plaques with no or minor smooth muscle cell (SMC)
staining vs. plaques with moderate or heavy smooth muscle cell
staining. H, I: Analysis of association between MMP-9 and Cav-1 levels in
plaques with no or minor macrophage (MO) staining vs. plaques with
moderate or heavy macrophage staining. Cav-1 levels are given as
mean and standard error. P-values were calculated comparing quartiles
1 and 2 to quartiles 3 and 4 with the Mann-Whitney U test. * denotes
p,0.05.
doi:10.1371/journal.pone.0002612.g003
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Cav-1 levels were strongly associated with features of plaque
vulnerability. Consistently, neo-intima formation after femoral cuff
placement was increased in Cav-1 null mice, which could be
reversed by addition of a MMP-inhibitor. Over-expression of the
active domain of Cav-1 impaired inflammation, MMP-activity
and arterial expansive remodeling. In addition to our descriptive
clinical data, we show that patients with high plaque Cav-1
expression seem to be protected from cardiovascular events within
30 days after surgery, making Cav-1 the first available plaque
biomarker with a prognostic value. The concept on local plaque
markers that are predictive for adverse cardiovascular events that
originate elsewhere in the vascular system is currently explored.
Several processes such as elevated proteolytic activity, inflam-
mation, and expansive remodeling are directly related to plaque
rupture [4;5;28]. Using different experimental approaches includ-
ing cultured cells, animal models and the determination of Cav-1
levels in plaque specimens, we have evaluated the involvement of
Table 3. Relations between clinical characteristics and Cav-1 expression levels.
Clinical characteristics prevalence (%) Cav-1 levels p-value
+ -
age.70 43% 18.0 (5.5–44.0) 20.5 (6.7–49.6) 0.29
male 68% 15.8 (4.7–36.6) 36.1 (15.5–62.4) ,0.001
hypertension 70% 19.5 (5.2–45.9) 22.3 (7.3–48.2) 0.42
diabetes 20% 17.6 (7.7–49.6) 19.6 (5.5–45.6) 0.90
smoking 26% 18.6 (6.2–48.3) 19.9 (5.4–46.0) 0.92
BMI .30 kg/m
2 14% 25.3 (5.5–50.2) 20.0 (6.7–47.1) 0.98
total cholesterol . 5.0 mmol/l 47% 22.9 (6.1–49.5) 19.8 (4.7–47.5) 0.55
HDL ,1.2 mmol/l 38% 22.1 (4.9–50.2) 20.1 (5.7–41.1) 0.58
LDL . 3.0 mmol/l 40% 20.3 (6.6–55.9) 22.2 (4.8–44.9) 0.90
triglycerides . 2.0 mmol/l 39% 24.6 (6.2–25.6) 19.4 (5.2–44.1) 0.36
hs-CRP . 3.4 mg/l 49% 20.0 (5.3–49.6) 22.3 (5.2–49.5) 0.94
Restenotic lesion 3% 6.1 (0.7–28.1) 19.7 (6.9–48.0) 0.04
History of myocardial infarction 20% 13.3 (3.2–40.7) 20.5 (7.4–48.4) 0.04
History of angina pectoris 35% 17.2 (3.9–44.7) 20.5 (7.7–48.4) 0.21
Intermittent claudication 46% 18.1 (4.5–46.2) 20.5 (6.8–46.2) 0.46
Medication
statin 64% 18.0 (4.6–46.0) 22.9 (8.0–46.2) 0.27
aspirin 84% 18.9 (5.4–48.6) 23.0 (10.2–45.7) 0.55
NSAID 6% 19.6 (9.8–53.7) 19.4 (5.7–46.0) 0.75
ACE inhibitor 43% 17.1 (4.8–45.3) 20.8 (7.2–49.3) 0.20
beta blocker 45% 19.8 (5.7–46.0) 18.3 (5.9–46.7) 0.62
Clinical presentation 0.13 *
asymptomatic 23% 23.6 (8.2–53.0)
ocular symptoms 14% 27.1 (10.2–45.9)
TIA 35% 15.3 (4.4–45.2)
stroke 28% 17.1 (7.7–48.2)
Median Cav-1 levels and interquartile range are given for patients in whom a clinical characteristic is present (+) or absent (2); e.g. age.70 (+) denotes the patient
group older than 70 years.
*TIA and stroke compared with asymptomatic
doi:10.1371/journal.pone.0002612.t003
Table 4. Occurrence of outcome events during follow-up.
follow-up interval
30 days total
person-years of follow-up* 31 625
vascular death 2 16
non-fatal ischemic stroke 2 11
non-fatal cerebral bleeding 1 1
non-fatal myocardial infarction 1 7
non-fatal ruptured aortic aneurysm 0 0
coronary revascularization 2 15
peripheral vascular intervention 0 42
*years of follow-up until occurrence of primary outcome event or end of follow-
up period
doi:10.1371/journal.pone.0002612.t004
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Cav-1 levels were inversely associated with MMP-9 activity and
the glycosylation status of the MMP inducer, known as
EMMPRIN, in carotid plaques. We next tested whether gelatinase
activity contributes to enhanced intimal hyperplasia development
in injured Cav-1 null femoral arteries. Here, we show that cuffed-
arteries in Cav-1 null mice have larger intimal area and intima-
media ratio than WT mice. These results are in line with a
previous study reporting that carotid artery ligation in Cav-1 null
resulted in an increased intimal area response [14]. Additionally,
we studied the contribution of gelatinase to intima formation in
Cav-1 null mice; MMPs were pharmacologically targeted using
the MMP inhibitor doxycycline. Besides its anti-microbial actions,
doxycycline is able to reduce expression and activity of several
MMPs, including MMP-2 and MMP-9 [30]. MMP inhibition in
Cav-1 null mice resulted in a significant attenuation of the
increased intimal formation in Cav-1 null mice.
The existence of a positive relationship between Cav-1 and
MMP-9 and the negative association with MMP-2 in the human
specimens is supporting previous observations in which MMP-9
but not MMP-2 is associated with a stable plaque phenotype [21].
In a previous study, we demonstrated that MMP-2 is strongly
associated with the presence of plaque stabilizing smooth muscle
cells while MMP-9 is associated with the presence of inflammatory
cells. Therefore, the negative association of Cav-1 with MMP-9
but not MMP-2 is supporting the hypothesis that Cav-1 is a plaque
stabilizing molecule. As mentioned earlier, EMMPRIN glycosyl-
ation has previously been associated with either a stable [the
45KD glycosylated form] or an unstable plaque phenotype [the
58KD glycosylated form] [21]. Therefore, we considered that
EMMPRIN glycosylation could be the mechanism by which
MMP-9 expression is controlled via Cav-1. For this reason the
expression of MMPs and EMMPRIN glycoslyation in relation to
Cav-1 were studied in more depth.
Intracellular delivery of peptides that mimic Cav-1 scaffolding
domain (CSD) (Cavtratin) in mouse macrophages and arterial
rings impaired gelatinase activity. These results are in agreement
with recently published data showing that Cav-1 inhibits MMP-2
activity in the heart and MMP-2 activity can be blocked using
purified CSD [31]. Another potential mechanism by which Cav-1
might affect MMP cascade might imply changes in glycosylation
status of EMMPRIN. It has been shown that up-regulation of
Cav-1 prevents transition of EMMPRIN to a highly glycosylated
(HG) form [32;33]. This HG-EMMPRIN forms a homodimer
and augments MMP production and subsequent activation
[32;33]. In our in vitro studies we could not demonstrate an
effect of Cavtratin on EMMPRIN levels and therefore we could
not prove that Cav-1 influences EMMPRIN glycosylation levels.
Whether the reduction of Cav-1 levels leads to an increase in
EMMPRIN 58kD glycosylation forms requires further investiga-
tion.
MMP-9 activity plays a major role in expansive remodeling in
animal models [5]. Expansive remodeling is clinically associated
with aortic aneurysms formation and a vulnerable atherosclerotic
plaque phenotype [28]. Previously, it was shown that pharma-
cological inhibition of MMPs impaired arterial expansion upon
vascular injury [34]. Therefore, we assessed the inhibitory
potential of Cavtratin on this process. Here we show that
treatment of mice with Cavtratin significantly reduced carotid
expansive remodeling after flow increase. Although mechanically
different, MMP-2 and MMP-9 are considered to play similar
roles in atherosclerotic expansive remodeling and flow induced
expansion of the artery. The current results therefore point to
another potential mechanism by which Cav-1 may prevent
plaque growth and destabilisation: expansively remodeled lesions
may hide accelerated plaque growth with formation of large
lipid pools with massive inflammatory response and protease
activity that remains clinically silent and untreated for a long
time.
We focused on protease activity as a mechanism by which Cav-
1 exerts protective effects that would explain the observed
outcomes in the clinical and animal studies. Although our results
Figure 4. Caveolin-1 and Vascular Outcomes during Follow-up. A - Caveolin-1 expression levels in the plaque in relation the occurrence of an
adverse vascular event within 30 days follow-up. *: p=0.03. B-Cumulative hazard of vascular events during long-term follow-up. The solid line
corresponds to patients with Cav-1 levels smaller than the median, and the dashed line corresponds to patients with Cav-1 levels larger than or equal
to the median. Hazard ratio=0.77 [0.48–1.23] (high vs. low Caveolin-1 expression)
doi:10.1371/journal.pone.0002612.g004
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protease activity, we cannot rule out that Cav-1 has broader anti-
inflammatory properties. The lower amount of IL-6 and IL-8
found in plaques with high Cav-1 content indeed suggests the
importance of Cav-1 in the regulation of pro-inflammatory
cascades associated with atherosclerosis. We also showed that
incubation with Cavtratin reduced COX-2 expression in LPS-
stimulated macrophages. Likewise, over-expression of Cav-1 full
length in macrophages was capable of reducing inflammation via a
MAPK-dependent mechanism [35].
The factors that are driving Cav-1 down-regulation during
atherogenesis need further investigation. The clinical descriptive
data obtained in this study may be helpful to generate hypothesis
to answer these questions. Interestingly, we have found that
women showed significantly higher Cav-1 expression levels than
men. It is known that Cav-1 expression levels are up-regulated
upon estrogen treatment in vascular smooth muscle cells [36].
Thus, this observation could suggest that Cav-1 is a potential
player in gender associated differences observed in atherosclerotic
disease [37]. Low expression levels of Cav-1 were observed in
restenotic plaques, although restenotic plaques in general have a
fibrous phenotype with high smooth muscle cell content.
However, these plaques are in a highly proliferative status. Cav-
1 is now recognized as an inhibitor of smooth muscle cell
proliferation and decreased Cav-1 expression has been linked to
increased smooth muscle cell proliferation in human atheroma
[16]. Thus, the low levels of Cav-1 found in restenotic and
unstable plaques could be related to a hyperproliferative cell
phenotype.
Next to the descriptive clinical observations, we also found a
relation between local Cav-1 expression and new peri-operative
(30 days) vascular events. The ATHERO-EXPRESS is the first
vascular bio-bank with a longitudinal design which allows studies
on locally expressed biomarkers in the atherosclerotic plaque as
surrogate marker to identify the so-called vulnerable patient [9].
This unique design allows investigating the process of atheroscle-
rotic plaque progression independent of the traditionally identified
Figure 5. Morphometric analysis of cuffed femoral arteries.
Total intimal area (A), medial area (B) and intima-media ratio (C) were
quantified by image analysis using 6 serial sections in each cuffed
artery. WT (n=11) values are represented by circles, Cav-1 null (n=10)
are shown as squares and Cav-1 null+DOX (n=9) are indicate as
triangles, ** p,0.001.
doi:10.1371/journal.pone.0002612.g005
Figure 6. Cavtratin, MMP-9 and EMMPRIN in Raw-264.7. A- Top,
representative zymogram of culture supernatant from Raw-264.7
macrophages. 1610
6 cells were incubated in a serum-free medium
with Cavtratin or scrambled peptides (10 mM) for a period of 24 hours.
Thereafter, culture media was collected and centrifuged for 5 minutes
at 2000 rpm at 4C and subjected to gelatin zymography. Little or
undetectable signal was observed for MMP-2. Middle, EMMPRIN
expression levels in total cell lysates obtained from Raw-264.7 cells
and representative western blot for b-actin (bottom panel). B-
Quantification of MMP-9 lytic activity in the culture supernatant. *
P=0.02. C- Quantification of EMMPRIN expression levels. Data
presented were normalized by b2actin expression.
doi:10.1371/journal.pone.0002612.g006
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In the current study, all patients in the group with high Cav-1
levels (.=median level) did not suffer any adverse event in the
peri-operative period. This suggests that down-regulation of Cav-1
levels in the vascular tree may induce a vulnerable status and
atherothrombotic events, while patients with high Cav-1 levels
seem protected. In addition, patients with a history of myocardial
infarction had lower levels of Cav-1, supporting the relation
between local plaque levels of Cav-1 and vulnerability for vascular
events. A systemic predisposition to vascular events and plaque
Figure 7. Cavtratin, MMP-9, COX-2 and EMMPRIN in LPS-challenged Raw-264.7. A- Top, MMP-9 activity in the culture supernatant from
Raw-264.7 macrophages. 1610
6 cells were pre-incubated in a serum-free medium with Cavtratin or scrambled peptides (10 mM) for a period of
8 hours. Thereafter, LPS (10ng/mL) was added and the culture media was collected after 20 hours of LPS addition and centrifuged for 5 minutes at
2000 rpm at 4C and subjected to gelatin zymography. Middle top, representative western blot showing EMMPRIN expression in total cell lysates
obtained from LPS-stimulated Raw-264.7 cells. Middle bottom, representative western blot for COX-2 expression in total cell lysates obtained from
LPS-stimulated Raw-264.7 cells. Bottom panel, representative western blot showing b-actin expression. B- Quantification of MMP-9 lytic activity in the
culture supernatant. * P,0.001. C- Quantification of EMMPRIN expression levels. Data presented were normalized by b2actin expression. D-
Quantification of COX-2 expression levels. Data presented were normalized by b2actin expression. * P,0.001
doi:10.1371/journal.pone.0002612.g007
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shown on basis of carotid angiograms [38] . Since the systemic
vulnerability ultimately leads to formation of an unstable plaque, it
is conceivable that the atherosclerotic plaque hides information
regarding systemic vulnerability. Although we observed a trend
towards lower risk of vascular events in patients with high Cav-1
during follow-up after 30 days, the difference was not statistically
significant.
In summary, our findings demonstrate a strong reduction of
Cav-1 levels in human carotid plaques in comparison to non-
atherosclerotic arteries. Low Cav-1 levels were associated with
signs of plaque vulnerability and conversely, plaque Cav-1 levels
showed a positive correlation with plaque stabilizing elements.
Clinical follow-up revealed that high Cav-1 levels were associated
with absence of major adverse cardiovascular events within 30
days of surgery.
Figure 8. Cavtratin and Gelatinase Activity in Porcine Arterial rings. A- Representative zymogram of tissue homogenates from porcine
arterial rings at baseline (0 days) and after 3 days in culture in the presence and/or absence of scrambled and Cavtratin peptides (10 mm). Data
represent 5 independent arterial rings., A representative western blot showing b-actin expression, demonstrating equal protein loading (bottom
panel). B- Quantification of total MMP-2 (Pro and active MMP-2) in porcine arterial rings after 3 days in culture in the presence and/or absence of
Cavtratin and scrambled (10 mm). Data represent 5 different arterial rings. * p=0.02 compared to untreated rings. C- Quantification of total MMP-9 in
porcine arteries after 3 days in culture in the presence or absence of Cavtratin and scrambled (10 mM). Data represent 5 different arterial rings. *
p=0.01 compared to untreated rings. D- In situ zymography obtained from cutured rings. Gelatinolytic activity is shown in green. Scale
bar=100 mm. L=Lumen.
doi:10.1371/journal.pone.0002612.g008
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targeting inflammation, tumor progression and right ventricle
hypertrophy [24;25;39], We provide evidence showing that Cav-
1 might act as a novel stabilizing factor in human atheroscle-
rosis.
Although our data demonstrate that Cav-1 expression levels
influence MMP activity within the plaques contributing to plaque
instability, we can not rule out at this point other possibilities
regarding how Cav-1 might influence plaque stability such as
reduction in the total number of Caveolae and/or effects on
plaque vascularisation.
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